PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.37%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
-2.64%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
0.38%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
3.04%
Positive EPS growth while CRVO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
3.04%
Positive diluted EPS growth while CRVO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
2.54%
Share count expansion well above CRVO's 0.68%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.54%
Diluted share count expanding well above CRVO's 0.68%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
10.47%
OCF growth under 50% of CRVO's 34.78%. Michael Burry might suspect questionable revenue recognition or rising costs.
10.65%
FCF growth under 50% of CRVO's 34.79%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12900.29%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-37006.68%
Negative 5Y OCF/share CAGR while CRVO is at 99.69%. Joel Greenblatt would question the firm’s operational model or cost structure.
-70.29%
Negative 3Y OCF/share CAGR while CRVO stands at 77.20%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-15642.97%
Negative 10Y net income/share CAGR while CRVO is at 19.53%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-43858.45%
Negative 5Y net income/share CAGR while CRVO is 99.06%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-130.01%
Negative 3Y CAGR while CRVO is 85.49%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
4179.35%
Positive 5Y equity/share CAGR while CRVO is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
1066.60%
3Y equity/share CAGR above 1.5x CRVO's 107.44%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-27.26%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-100.00%
We’re deleveraging while CRVO stands at 341.82%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
37.07%
R&D growth drastically higher vs. CRVO's 34.39%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-49.28%
We cut SG&A while CRVO invests at 63.99%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.